Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16), Bloomberg Earnings reports. During the same period last year, the company posted ($0.14) EPS.
Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 4.81 on Thursday. The stock’s market cap is $657.64 million. The stock has a 50 day moving average price of $4.37 and a 200-day moving average price of $4.12. Achillion Pharmaceuticals has a 12-month low of $3.15 and a 12-month high of $9.49.
ACHN has been the subject of a number of recent research reports. BidaskClub downgraded Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Chardan Capital cut their price objective on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 10th. Robert W. Baird downgraded Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price objective for the company. in a research report on Thursday. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Wednesday, April 26th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $8.25.
TRADEMARK VIOLATION WARNING: This piece was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/08/10/achillion-pharmaceuticals-inc-achn-releases-earnings-results-meets-expectations.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.